<DOC>
	<DOCNO>NCT02015234</DOCNO>
	<brief_summary>This Phase 3 , open-label , extension trial design evaluate long-term safety 12 month TNX-102 SL tablet take daily bedtime treatment FM . Patients recruit trial successfully complete double-blind study , TNX-CY-F202 ( F202 ) . Patients make aware therapy receive double-blind study .</brief_summary>
	<brief_title>12-Month Open-Label Long-term Safety Study TNX-102 SL Tablets Fibromyalgia Patients</brief_title>
	<detailed_description>The study consist 7 clinic visit , include Screening/Baseline Visit 1 ( Day 0 , anticipate date Visit 6 F202 ) , visit 1 , 3 , 6 , 9 , 12 month treatment ( Visits 2-6 ) , Follow-up Visit ( Visit 7 ) schedule within one month stop study drug treatment . Primary : The primary objective study evaluate long-term safety TNX-102 SL tablet take daily bedtime 12 month patient FM complete Study TNX-CY-F202 Secondary : The secondary objective evaluate long-term efficacy TNX-102 SL tablet take daily bedtime control symptoms FM</detailed_description>
	<mesh_term>Fibromyalgia</mesh_term>
	<mesh_term>Myofascial Pain Syndromes</mesh_term>
	<mesh_term>Cyclobenzaprine</mesh_term>
	<criteria>1 . The patient meet prior inclusion exclusion requirement Study F202 originally , intervene medical condition , increase suicidal ideation , requirement concomitant medication preclude exposure TNX102 SL enrollment extension study . 2 . The patient complete expect dose F202 define take study medication Week 12 , least 70 % compliance medication usage ( base response daily IVRS call record F202 study ) major protocol violation . 3 . The patient provide write informed consent participate extension protocol .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>October 2015</verification_date>
	<keyword>TNX-102 SL</keyword>
	<keyword>bedtime</keyword>
	<keyword>sublingual</keyword>
	<keyword>12-month</keyword>
	<keyword>long term safety</keyword>
	<keyword>long term efficacy</keyword>
	<keyword>Fibromyalgia</keyword>
</DOC>